LGD-4033 and Oxytocin Interaction: Monitor | Peptide Database

FDA-approved for reduction of elevated total cholesterol and LDL-C in patients with primary hyperlipidemia, either as monotherapy or in combination with a statin. Reduces LDL by approximately 18% as monotherapy and provides an additional 25% reduction when added to ongoing statin therapy. Widely used off-label by anabolic steroid users to counteract the significant lipid disturbances caused by AAS, particularly oral 17-alpha-alkylated steroids. Oral compounds like oxandrolone can reduce HDL by 50% or more and elevate LDL substantially. Ezetimibe helps blunt LDL elevation while its non-hepatotoxic profile makes it preferable to statins during cycles involving liver-stressing orals. When LDL targets are not achieved with statin monotherapy, adding ezetimibe provides a complementary mechanism of action. The IMPROVE-IT trial demonstrated that the combination of ezetimibe plus simvastatin reduced cardiovascular events compared to simvastatin alone in post-acute coronary syndrome patients. The IMPROVE-IT trial established that adding ezetimibe to simvastatin therapy reduced the composite endpoint of cardiovascular death, major coronary events, and stroke by 6.4% over 7 years in patients with recent acute coronary syndrome. This was the first trial to demonstrate that a non-statin LDL-lowering agent provides incremental cardiovascular benefit. Approved as adjunctive therapy for homozygous familial hypercholesterolemia (HoFH) in combination with statins. Also used in heterozygous FH when statin monotherapy is insufficient to reach LDL targets. Particularly useful in patients who cannot tolerate high-dose statins.

Enhances memory consolidation and spatial learning in animal models through FGFR1-mediated synaptic plasticity. Preclinical evidence suggests potential to counteract age-related cognitive decline via neurogenesis and synaptic support. Animal studies demonstrate reduced infarct volume and improved functional outcomes following ischemic injury. Shows protective effects in preclinical models of Alzheimer's disease and other neurodegenerative conditions. Promotes long-term potentiation and strengthens synaptic connections through FGFR1 activation. Stimulates the generation of new neurons in the hippocampus in animal models.